Dole plc Reports First Quarter 2022 Financial Results
Dole plc (NYSE: DOLE) announced its Q1 2022 financial results, reporting revenue of $2.2 billion, net income of $3.3 million, and diluted EPS of $(0.01). Adjusted EBITDA stood at $81.5 million. Year-over-year revenue grew significantly due to acquisition impacts, while pro-forma comparisons showed a slight decline, primarily from a Value Added salads recall and currency translation effects. For FY 2022, Dole projects revenue between $9.4 billion and $9.7 billion, with adjusted EBITDA expected between $350 million and $370 million.
- Q1 2022 revenue increased to $2.2 billion from $1.1 billion year-over-year.
- Adjusted net income rose to $28.2 million from $25.9 million in the prior year.
- Dole is targeting 2022 revenue of $9.4 to $9.7 billion.
- Adjusted EBITDA for Q1 2022 was $81.5 million, despite challenges.
- Net income decreased from $26.1 million in Q1 2021 to $3.3 million in Q1 2022.
- Diluted EPS declined from $0.38 in Q1 2021 to $(0.01) in Q1 2022.
- Adjusted EBITDA decreased from $131.1 million on a pro-forma basis.
- Fresh Vegetables revenue dropped 16.2% compared to the prior year pro-forma.
Highlights for Q1'22:
-
Revenue of
$2.2 billion -
Net Income of
and Diluted EPS of$3.3 million $(0.01) -
Adjusted EBITDA1 of
$81.5 million -
Adjusted Net Income1 of
and Adjusted Diluted EPS1 of$28.2 million $0.30
Financial Highlights - Unaudited
|
Q1'22 |
Q1'21 |
Q1'21 Pro-forma (2) |
Revenue - $’m |
2,245 |
1,051 |
2,266 |
Net Income - $'m |
3.3 |
26.1 |
63.2 |
Net (Loss) Income attributable to |
(1.4) |
21.3 |
57.7 |
Diluted EPS - $ |
(0.01) |
0.38 |
0.61 |
Adjusted EBITDA - $’m (1) |
81.5 |
79.2 |
131.1 |
Adjusted Net Income - $’m (1) |
28.2 |
25.9 |
58.8 |
Adjusted Diluted EPS - $ (1) |
0.30 |
0.46 |
0.62 |
Commenting on the results,
“We are pleased with the result that the Group has delivered for the first quarter of 2022 particularly as we were impacted by the Value Added salads recall and foreign currency translation movements in the quarter. Our diversified business model has once more proven itself to be resilient. For the 2022 financial year, we are now targeting revenue in the range of
Revenue for the first quarter increased to
Adjusted EBITDA for the first quarter increased to
Adjusted Net Income for the first quarter was
Selected Segmental Financial Information (Unaudited)
|
Q1'22 |
|
Q1'21 - Pro-forma |
|||||||||||
|
( |
|||||||||||||
|
Revenue |
|
Adjusted EBITDA |
|
Revenue |
|
Adjusted EBITDA |
|||||||
Fresh Fruit |
$ |
749,803 |
|
|
$ |
61,881 |
|
|
$ |
744,614 |
|
|
$ |
91,587 |
|
|
791,155 |
|
|
|
20,101 |
|
|
|
793,740 |
|
|
|
24,927 |
|
|
463,692 |
|
|
|
12,303 |
|
|
|
421,693 |
|
|
|
10,096 |
Fresh Vegetables |
|
274,751 |
|
|
|
(12,746 |
) |
|
|
327,701 |
|
|
|
4,534 |
Intersegment |
|
(34,419 |
) |
|
|
— |
|
|
|
(21,985 |
) |
|
|
— |
Total |
$ |
2,244,982 |
|
|
$ |
81,539 |
|
|
$ |
2,265,763 |
|
|
$ |
131,144 |
Fresh Fruit
Revenue for the first quarter increased
Adjusted EBITDA for the first quarter decreased
Revenue for the first quarter was broadly in line with the prior year pro-forma comparative. On a like-for-like basis, strong revenue growth was seen across the division, largely driven by higher prices across most regions as well as by increased food service revenue, particularly in the
Adjusted EBITDA for the first quarter decreased
Revenue for the first quarter increased
Adjusted EBITDA for the first quarter increased
Fresh Vegetables
Revenue for the first quarter decreased
Adjusted EBITDA for the first quarter was a loss of
Capital Expenditures
Capital expenditures for the first quarter of 2022 was
Net Debt and Financial Leverage
Net Debt as of
Outlook for Fiscal Year 2022 (forward-looking statement)
For fiscal year 2022, Dole is targeting:
-
Revenue in the range of
to$9.4 billion $9.7 billion -
Adjusted EBITDA in the range of
to$350.0 million $370.0 million -
Capital Expenditures of approximately
$125.0 million -
Net Interest Expense of approximately
$45.0 million -
Adjusted Effective tax rate in the range of
23.0% to27.0%
The reduction in targeted Adjusted EBITDA is primarily due to a slower than anticipated return to full operating profitability in our Fresh Vegetables segment and a more negative foreign currency translation impact on translation of Euro earnings to
The geopolitical situation in
The above outlook includes non-GAAP financial measures. Please refer to the end of this release for an explanation and reconciliation of our historical non-GAAP financial measures used in this release to comparable GAAP measures.
Dividend
On
Consolidated Statement of Operations - Unaudited
|
Three Months Ended |
||||||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
Pro-forma |
||||||
|
( |
||||||||||
Revenues, net |
$ |
2,244,982 |
|
|
$ |
1,051,139 |
|
|
$ |
2,265,763 |
|
Cost of sales |
|
(2,110,943 |
) |
|
|
(966,638 |
) |
|
|
(2,043,829 |
) |
Gross profit |
|
134,039 |
|
|
|
84,501 |
|
|
|
221,934 |
|
Selling, marketing, general and administrative expenses |
|
(124,159 |
) |
|
|
(66,751 |
) |
|
|
(135,930 |
) |
Merger, transaction and other related costs |
|
— |
|
|
|
(6,777 |
) |
|
|
— |
|
Gain on disposal of businesses |
|
242 |
|
|
|
1,539 |
|
|
|
1,539 |
|
Gain on asset sales |
|
495 |
|
|
|
— |
|
|
|
3,582 |
|
Operating income |
|
10,617 |
|
|
|
12,512 |
|
|
|
91,125 |
|
Other income, net |
|
2,517 |
|
|
|
295 |
|
|
|
4,941 |
|
Interest income |
|
1,638 |
|
|
|
417 |
|
|
|
1,108 |
|
Interest expense |
|
(11,644 |
) |
|
|
(2,252 |
) |
|
|
(11,292 |
) |
Income before income taxes and equity earnings |
|
3,128 |
|
|
|
10,972 |
|
|
|
85,882 |
|
Income tax expense |
|
(420 |
) |
|
|
(1,256 |
) |
|
|
(23,991 |
) |
Equity in net earnings of investments accounted for under the equity method |
|
577 |
|
|
|
16,399 |
|
|
|
1,305 |
|
Net income |
|
3,285 |
|
|
|
26,115 |
|
|
|
63,196 |
|
Less: Net income attributable to noncontrolling interests |
|
(4,679 |
) |
|
|
(4,806 |
) |
|
|
(5,546 |
) |
Net income (loss) attributable to |
$ |
(1,394 |
) |
|
$ |
21,309 |
|
|
$ |
57,650 |
|
|
|
|
|
|
|
||||||
Net income (loss) per share attributable to |
$ |
(0.01 |
) |
|
$ |
0.38 |
|
|
$ |
0.61 |
|
Net income (loss) per share attributable to |
$ |
(0.01 |
) |
|
$ |
0.38 |
|
|
$ |
0.61 |
|
Weighted average shares outstanding - basic |
|
94,878 |
|
|
|
55,532 |
|
|
|
94,878 |
|
Weighted average shares outstanding - diluted |
|
94,878 |
|
|
|
55,699 |
|
|
|
95,030 |
|
Consolidated Balance Sheets - Unaudited
|
|
|
|
||||
ASSETS |
( |
||||||
Cash and cash equivalents |
$ |
215,948 |
|
|
$ |
250,561 |
|
Short-term investments |
|
5,584 |
|
|
|
6,115 |
|
Trade receivables, net of allowances for credit losses of |
|
785,626 |
|
|
|
719,114 |
|
Grower advance receivables, net of allowances of |
|
102,709 |
|
|
|
72,350 |
|
Other receivables, net of allowances of |
|
137,162 |
|
|
|
125,908 |
|
Inventories, net of allowances of |
|
457,660 |
|
|
|
410,737 |
|
Prepaid expenses |
|
58,214 |
|
|
|
45,339 |
|
Other current assets |
|
16,309 |
|
|
|
11,011 |
|
Assets held-for-sale |
|
2,974 |
|
|
|
200 |
|
Total current assets |
|
1,782,186 |
|
|
|
1,641,335 |
|
Long-term investments |
|
21,405 |
|
|
|
23,433 |
|
Investments in unconsolidated affiliates |
|
126,846 |
|
|
|
128,407 |
|
Actively marketed property |
|
37,001 |
|
|
|
50,364 |
|
Property, plant and equipment, net of accumulated depreciation of |
|
1,394,556 |
|
|
|
1,430,850 |
|
Operating lease right-of-use assets |
|
363,045 |
|
|
|
368,632 |
|
|
|
509,174 |
|
|
|
511,333 |
|
DOLE brand |
|
306,280 |
|
|
|
306,280 |
|
Other intangible assets, net of accumulated amortization of |
|
59,674 |
|
|
|
62,046 |
|
Other assets |
|
125,855 |
|
|
|
98,917 |
|
Deferred income tax assets |
|
47,238 |
|
|
|
46,371 |
|
Total assets |
$ |
4,773,260 |
|
|
$ |
4,667,968 |
|
LIABILITIES AND EQUITY |
|
|
|
||||
Accounts payable |
$ |
695,513 |
|
|
$ |
696,766 |
|
Income taxes payable |
|
5,427 |
|
|
|
10,316 |
|
Accrued liabilities |
|
429,297 |
|
|
|
464,931 |
|
Bank overdrafts |
|
15,883 |
|
|
|
9,395 |
|
Notes payable and current portion of long-term debt, net |
|
83,792 |
|
|
|
51,785 |
|
Current maturities of operating leases |
|
73,292 |
|
|
|
73,046 |
|
Other tax |
|
36,125 |
|
|
|
35,212 |
|
Contingent consideration |
|
3,037 |
|
|
|
2,958 |
|
Pension and postretirement benefits |
|
17,857 |
|
|
|
17,664 |
|
Dividends payable and other current liabilities |
|
18,232 |
|
|
|
9,078 |
|
Total current liabilities |
|
1,378,455 |
|
|
|
1,371,151 |
|
Long-term debt, net |
|
1,387,941 |
|
|
|
1,297,808 |
|
Operating leases, less current maturities |
|
298,194 |
|
|
|
305,714 |
|
Deferred income tax liabilities |
|
149,307 |
|
|
|
145,689 |
|
Income tax payable, less current portion |
|
40,439 |
|
|
|
40,439 |
|
Contingent consideration, less current portion |
|
4,106 |
|
|
|
4,302 |
|
Pension and postretirement benefits, less current portion |
|
147,621 |
|
|
|
152,149 |
|
Other long-term liabilities |
|
105,944 |
|
|
|
105,310 |
|
Total liabilities |
$ |
3,512,007 |
|
|
$ |
3,422,562 |
|
Commitments and contingent liabilities (See Note 16) |
|
|
|
||||
Redeemable noncontrolling interests. |
|
33,949 |
|
|
|
32,776 |
|
Stockholders’ equity: |
|
|
|
||||
Common stock |
|
950 |
|
|
|
950 |
|
Additional paid-in capital |
|
792,061 |
|
|
|
792,223 |
|
Retained earnings |
|
404,334 |
|
|
|
413,335 |
|
Accumulated other comprehensive loss |
|
(100,962 |
) |
|
|
(125,919 |
) |
Total equity attributable to |
|
1,096,383 |
|
|
|
1,080,589 |
|
Equity attributable to noncontrolling interests |
|
130,921 |
|
|
|
132,041 |
|
Total equity |
|
1,227,304 |
|
|
|
1,212,630 |
|
Total liabilities, redeemable noncontrolling interests and equity |
$ |
4,773,260 |
|
|
$ |
4,667,968 |
|
Consolidated Statements of Cash Flows - Unaudited
|
Three Months Ended |
||||||
|
|
|
|
||||
|
|
|
|
||||
Operating Activities |
( |
||||||
Net income |
$ |
3,285 |
|
|
$ |
26,115 |
|
Adjustments to reconcile net income to net cash used in operating activities: |
|
|
|
||||
Depreciation and amortization |
|
31,013 |
|
|
|
9,480 |
|
Incremental charges on purchase accounting valuation of biological assets |
|
17,513 |
|
|
|
— |
|
Asset write-offs and net gain on sale of assets |
|
(495 |
) |
|
|
— |
|
Net loss on financial instruments |
|
506 |
|
|
|
— |
|
Stock-based compensation expense |
|
648 |
|
|
|
— |
|
Earnings from equity method investments |
|
(577 |
) |
|
|
(16,399 |
) |
Net gain on disposal of businesses |
|
(242 |
) |
|
|
(1,539 |
) |
Amortization of debt discounts and debt issuance costs |
|
1,466 |
|
|
|
— |
|
Benefit for deferred income taxes |
|
(4,078 |
) |
|
|
(539 |
) |
Pension and other postretirement benefit plan benefit |
|
(1,023 |
) |
|
|
(415 |
) |
Fair value movement on contingent consideration |
|
25 |
|
|
|
41 |
|
Dividends received |
|
810 |
|
|
|
2,075 |
|
Other |
|
(234 |
) |
|
|
2,084 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables, net of allowances |
|
(114,022 |
) |
|
|
(39,994 |
) |
Inventories |
|
(48,762 |
) |
|
|
(3,811 |
) |
Operating lease liabilities |
|
1,037 |
|
|
|
2,276 |
|
Accrued and other current and long-term liabilities |
|
(32,161 |
) |
|
|
(17,053 |
) |
Cash flow used in operating activities |
|
(145,291 |
) |
|
|
(37,679 |
) |
Investing Activities |
|
|
|
||||
Sales of assets |
|
15,620 |
|
|
|
— |
|
Capital expenditures |
|
(17,330 |
) |
|
|
(8,669 |
) |
Acquisitions, net of cash acquired |
|
(1,399 |
) |
|
|
— |
|
Insurance proceeds received for damage to property |
|
776 |
|
|
|
— |
|
Purchases of investments |
|
(412 |
) |
|
|
— |
|
Investments in unconsolidated affiliates |
|
(48 |
) |
|
|
(596 |
) |
Other |
|
3 |
|
|
|
147 |
|
Cash flow used in investing activities |
|
(2,790 |
) |
|
|
(9,118 |
) |
Financing Activities |
|
|
|
||||
Proceeds from borrowings and overdrafts |
|
341,795 |
|
|
|
551,306 |
|
Repayments on borrowings and overdrafts |
|
(212,414 |
) |
|
|
(289,475 |
) |
Payment of debt issuance costs |
|
— |
|
|
|
(7,500 |
) |
Dividends paid to shareholders |
|
(7,590 |
) |
|
|
(4,307 |
) |
Dividends paid to noncontrolling interests |
|
(3,616 |
) |
|
|
(2,174 |
) |
Payment of contingent consideration |
|
(599 |
) |
|
|
— |
|
Cash flow provided by financing activities |
|
117,576 |
|
|
|
247,850 |
|
Effect of foreign currency exchange rate changes on cash |
|
(4,108 |
) |
|
|
(3,206 |
) |
(Decrease) increase in cash and cash equivalents |
|
(34,613 |
) |
|
|
197,847 |
|
Cash and cash equivalents at beginning of period |
|
250,561 |
|
|
|
160,503 |
|
Cash and cash equivalents at end of period |
$ |
215,948 |
|
|
$ |
358,350 |
|
|
|
|
|
Reconciliation from Net Income to Adjusted EBITDA - Unaudited
|
Three Months Ended |
||||||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
Pro-forma |
||||||
|
( |
||||||||||
|
|
|
|
|
|
||||||
Net income |
$ |
3,285 |
|
|
$ |
26,115 |
|
|
$ |
63,196 |
|
Interest expense |
|
11,644 |
|
|
|
2,252 |
|
|
|
11,292 |
|
Income tax expense |
|
420 |
|
|
|
1,256 |
|
|
|
23,991 |
|
EBIT |
|
15,349 |
|
|
|
29,623 |
|
|
|
98,479 |
|
Depreciation |
|
28,171 |
|
|
|
6,705 |
|
|
|
28,318 |
|
Amortization of intangible assets |
|
2,842 |
|
|
|
2,775 |
|
|
|
2,775 |
|
Merger, transaction, and other related costs |
|
— |
|
|
|
6,777 |
|
|
|
— |
|
Net unrealized (gain) loss on derivative instruments |
|
(4,088 |
) |
|
|
219 |
|
|
|
463 |
|
Net unrealized (gain) on foreign currency denominated borrowings |
|
(1,491 |
) |
|
|
— |
|
|
|
(5,859 |
) |
Net noncash realized (gain) on foreign currency denominated borrowings |
|
(1,029 |
) |
|
|
— |
|
|
|
— |
|
Produce recalls |
|
16,251 |
|
|
|
— |
|
|
|
— |
|
Fair value movement on contingent consideration |
|
25 |
|
|
|
41 |
|
|
|
41 |
|
Asset write-downs, net of insurance proceeds |
|
(626 |
) |
|
|
— |
|
|
|
(9,880 |
) |
Restructuring charges |
|
— |
|
|
|
— |
|
|
|
(125 |
) |
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
17,513 |
|
|
|
— |
|
|
|
— |
|
(Gain) on disposal of businesses |
|
(242 |
) |
|
|
(1,539 |
) |
|
|
(1,539 |
) |
Net realized foreign currency loss on liquidated entities |
|
5,445 |
|
|
|
— |
|
|
|
— |
|
Legal matters |
|
— |
|
|
|
— |
|
|
|
15,000 |
|
Items in earnings for equity method investments: |
|
|
|
|
|
||||||
Dole's share of interest expense |
|
556 |
|
|
|
7,257 |
|
|
|
334 |
|
Dole's share of income tax |
|
561 |
|
|
|
15,675 |
|
|
|
855 |
|
Dole's share of depreciation |
|
1,624 |
|
|
|
11,582 |
|
|
|
1,556 |
|
Dole's share of amortization |
|
666 |
|
|
|
726 |
|
|
|
726 |
|
Dole's share of other items |
|
12 |
|
|
|
(687 |
) |
|
|
— |
|
Adjusted EBITDA |
$ |
81,539 |
|
|
$ |
79,154 |
|
|
$ |
131,144 |
|
Reconciliation from Net (Loss) Income attributable to
|
Three Months Ended |
||||||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
Pro-forma |
||||||
|
( |
||||||||||
|
|
|
|
|
|
||||||
(Loss) income for the financial year attributable to equity shareholders |
$ |
(1,394 |
) |
|
$ |
21,309 |
|
|
$ |
57,650 |
|
Adjustments: |
|
|
|
|
|
||||||
Amortization of intangible assets |
|
2,842 |
|
|
|
2,775 |
|
|
|
2,775 |
|
Net unrealized (gain) loss on derivative financial instruments |
|
(4,088 |
) |
|
|
219 |
|
|
|
463 |
|
Merger, transaction, and other related costs |
|
— |
|
|
|
6,777 |
|
|
|
— |
|
Net unrealized (gain) on foreign currency denominated borrowings |
|
(1,491 |
) |
|
|
— |
|
|
|
(5,859 |
) |
Net noncash realized (gain) on foreign currency denominated borrowings |
|
(1,029 |
) |
|
|
— |
|
|
|
— |
|
Produce recall costs |
|
16,251 |
|
|
|
— |
|
|
|
— |
|
Fair value movements on contingent consideration |
|
25 |
|
|
|
41 |
|
|
|
41 |
|
Asset write-downs, net of insurance proceeds |
|
(626 |
) |
|
|
— |
|
|
|
(9,880 |
) |
Restructuring charges |
|
— |
|
|
|
— |
|
|
|
(125 |
) |
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
17,513 |
|
|
|
— |
|
|
|
— |
|
(Gain) on disposal of businesses |
|
(242 |
) |
|
|
(1,539 |
) |
|
|
(1,539 |
) |
Net realized foreign currency loss on liquidated entities |
|
5,445 |
|
|
|
— |
|
|
|
— |
|
Legal matters |
|
— |
|
|
|
— |
|
|
|
15,000 |
|
Income tax on items above |
|
(5,249 |
) |
|
|
(8 |
) |
|
|
(2,254 |
) |
Income tax on discrete tax items |
|
250 |
|
|
|
— |
|
|
|
2,520 |
|
Deferred tax on intangible assets |
|
(125 |
) |
|
|
(389 |
) |
|
|
(389 |
) |
NCI impact on items above |
|
(458 |
) |
|
|
(914 |
) |
|
|
(259 |
) |
Items in earnings for equity method investments |
|
|
|
|
|
||||||
Dole's share of amortization on intangible assets |
|
666 |
|
|
|
726 |
|
|
|
726 |
|
Dole's share of other items |
|
12 |
|
|
|
(687 |
) |
|
|
— |
|
Dole's share of income tax on items above |
|
(103 |
) |
|
|
(2,410 |
) |
|
|
(120 |
) |
Adjusted Net Income for Adjusted EPS calculation |
$ |
28,199 |
|
|
$ |
25,900 |
|
|
$ |
58,750 |
|
|
|
|
|
|
|
||||||
Adjusted earnings per share - basic |
$ |
0.30 |
|
|
$ |
0.47 |
|
|
$ |
0.62 |
|
Adjusted earnings per share - diluted |
$ |
0.30 |
|
|
$ |
0.46 |
|
|
$ |
0.62 |
|
Weighted average shares outstanding - basic |
|
94,878 |
|
|
|
55,532 |
|
|
|
94,878 |
|
Weighted average shares outstanding - diluted |
|
94,878 |
|
|
|
55,699 |
|
|
|
95,030 |
|
Net Debt and Financial Leverage
Net Debt is the primary measure used by management to analyze the Company’s capital structure and financial leverage. Net Debt is a non-GAAP financial measure, calculated as cash and cash equivalents, less current and long-term debt. It also excludes debt discounts and debt issuance costs. The calculation of Net Debt and financial leverage as of
|
|
||
|
Unaudited |
||
|
( |
||
Cash and cash equivalents |
$ |
(215,948 |
) |
Bank overdrafts |
|
15,883 |
|
Notes payable and current portion of long-term debt, net |
|
83,792 |
|
Long-term debt, net. |
|
1,387,941 |
|
|
|
1,271,668 |
|
Less: Debt discounts and debt issuance costs |
|
19,894 |
|
Net Debt |
$ |
1,291,562 |
|
|
|
||
Pro-forma Adjusted EBITDA for 12 months ended |
|
343,976 |
|
Financial Leverage: Net Debt / Pro-forma Adjusted EBITDA |
3.75x |
Dole plc’s results are determined in accordance with
In addition to its results under
Adjusted EBITDA is calculated from EBIT by: (1) adding depreciation charges; (2) adding amortization charges; (3) adding merger, transaction and other related costs; (4) adding the net unrealized loss or subtracting the net unrealized gain on derivative instruments; (5) adding the net unrealized loss or subtracting the net unrealized gain on foreign currency denominated borrowings; (6) adding the net realized loss or subtracting the net realized gain on noncash settled foreign currency denominated borrowings; (7) adding or subtracting fair value movements on contingent consideration; (8) adding impairment charges on property, plant and equipment; (9) adding or subtracting asset write-downs, net of insurance proceeds; (10) adding incremental costs for produce recalls and related costs; (11) subtracting the fair value gain or adding the fair value loss on the acquisition of investments previously accounted for under the equity method; (12) subtracting the gain or adding the loss on the sale of investments accounted for under the equity method; (13) subtracting the gain or adding the loss on the disposal of business interests; (14) adding the net realized foreign currency loss or subtracting the net realized foreign currency gain on liquidated entities; (15) adding the loss or subtracting the gain on asset sales for assets held-for-sale and actively marketed property; (16) adding the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole; (17) adding restructuring charges; and (18) adding costs for legal matters not in the ordinary course of business. It also includes the effect of the Company’s share of all listed items within investments accounted for under the equity method.
Adjusted Net Income is calculated from net income (loss) attributable to
Adjusted Earnings per Share is calculated from Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Adjusted Effective tax rate is calculated from the effective tax rate by: (1) subtracting the impact from incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole; and (2) subtracting the impact from uncertain tax positions.
Pro-forma EBIT is calculated from pro-forma net income (loss) by adding pro-forma interest expense and adding the pro-forma income tax expense or subtracting the pro-forma income tax benefit.
Pro-forma Adjusted EBITDA is calculated from pro-forma EBIT by: (1) adding depreciation charges; (2) adding amortization charges; (3) adding merger, transaction and other related costs; (4) adding the net unrealized loss or subtracting the net unrealized gain on derivative instruments; (5) adding the net unrealized loss or subtracting the net unrealized gain on foreign currency denominated borrowings; (6) adding the net realized loss or subtracting the net realized gain on noncash settled foreign currency denominated borrowings; (7) adding or subtracting fair value movements on contingent consideration; (8) adding impairment charges on property, plant and equipment; (9) adding or subtracting asset write-downs, net of insurance proceeds; (10) adding incremental costs for produce recalls and related costs; (11) subtracting the fair value gain or adding the fair value loss on the acquisition of investments previously accounted for under the equity method; (12) subtracting the gain or adding the loss on the sale of investments accounted for under the equity method; (13) subtracting the gain or adding the loss on the disposal of business interests; (14) adding the net realized foreign currency loss or subtracting the net realized foreign currency gain on liquidated entities; (15) adding the loss or subtracting the gain on asset sales for assets held-for-sale and actively marketed property; (16) adding the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole; (17) adding restructuring charges; and (18) and adding costs for legal matters not in the ordinary course of business. It also includes the effect of the Company’s share of all listed items within investments accounted for under the equity method.
Pro-forma Adjusted Net Income is calculated from pro-forma net income (loss) attributable to
Pro-forma Adjusted Earnings per Share is calculated from pro-forma Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Pro-forma EBIT, Adjusted EBITDA, pro-forma Adjusted EBITDA, Adjusted Net Income, pro-forma Adjusted Net Income, Adjusted Effective tax rate, Adjusted EPS and pro-forma Adjusted EPS are not measurements of
- They do not reflect Dole plc’s cash expenditures, or future requirements, for capital expenditures or contractual commitments;
- They do not reflect changes in, or cash requirements for, Dole plc’s working capital needs;
- They do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on Dole plc’s debt; and
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and these non-GAAP financial measures do not reflect cash requirements for such replacements.
Because of these limitations, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS should not be considered as measures of discretionary cash available to
Further, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-form Adjusted EPS as used herein may not be calculated in a similar manner to, and are therefore not necessarily comparable with, similarly titled measures of other companies. However, we have included pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma EPS herein because Dole plc’s management believes that pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS are useful performance measures.
Dole is not able to provide a reconciliation for projected FY'22 Adjusted EBITDA and Adjusted Effective tax rate without undertaking unreasonable efforts.
Pro-forma Methodology
The methodology used to prepare the unaudited pro-forma consolidated financial statements for
1. All associated transaction costs reflected on
2. Effective tax rate of
3. Applying the results of the Purchase Price Allocation (“PPA”) exercise, acquisition accounting and debt refinancing to
a. Q1 2021 pro-forma results reflect a reduction in the depreciation charge of
b. The interest expense for Q1 2021 reflects the outcome of the refinancing.
4. TP’s pickup of its
5. EPS is calculated using shares in issue following the IPO and additional share issuances.
6. There is an adjustment in Q1 2021 of
See reconciliation of pro-forma results for the three months ended
Pro-forma Reconciliation (Unaudited) – for the three months ended
|
TP |
DFC |
|
FV &
|
Transaction
|
Ongoing
|
Debt
|
Tax
|
Pro-forma
|
|||||||||
|
( |
|||||||||||||||||
Revenues, net |
1,051,139 |
|
1,232,674 |
|
2,283,813 |
|
(18,050 |
) |
— |
— |
|
— |
|
— |
|
|
2,265,763 |
|
Cost of sales |
(966,638 |
) |
(1,096,241 |
) |
(2,062,879 |
) |
19,050 |
|
— |
— |
|
— |
|
— |
|
|
(2,043,829 |
) |
Gross profit |
84,501 |
|
136,433 |
|
220,934 |
|
1,000 |
|
— |
— |
|
— |
|
— |
|
|
221,934 |
|
Selling, marketing and general and administrative expenses |
(66,383 |
) |
(64,522 |
) |
(130,905 |
) |
— |
|
— |
(5,025 |
) |
— |
|
— |
|
|
(135,930 |
) |
Merger, transaction, and other related costs |
(6,777 |
) |
(387 |
) |
(7,164 |
) |
— |
|
7,164 |
— |
|
— |
|
— |
|
|
— |
|
Gain on disposal of businesses |
1,539 |
|
— |
|
1,539 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
1,539 |
|
Gain on asset sales |
— |
|
3,582 |
|
3,582 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
3,582 |
|
Operating income (loss) |
12,880 |
|
75,106 |
|
87,986 |
|
1,000 |
|
7,164 |
(5,025 |
) |
— |
|
— |
|
|
91,125 |
|
Other income (expense), net |
(73 |
) |
5,014 |
|
4,941 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
4,941 |
|
Interest income |
417 |
|
691 |
|
1,108 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
1,108 |
|
Interest expense |
(2,252 |
) |
(16,631 |
) |
(18,883 |
) |
— |
|
— |
— |
|
7,591 |
|
— |
|
|
(11,292 |
) |
Income (loss) before income taxes and equity earnings |
10,972 |
|
64,180 |
|
75,152 |
|
1,000 |
|
7,164 |
(5,025 |
) |
7,591 |
|
— |
|
|
85,882 |
|
Income tax (expense) benefit |
(1,256 |
) |
(20,775 |
) |
(22,031 |
) |
— |
|
— |
1,580 |
|
(2,387 |
) |
(1,153 |
) |
|
(23,991 |
) |
Equity in net earnings of investments accounted for under the equity method |
16,399 |
|
252 |
|
16,651 |
|
(15,346 |
) |
— |
— |
|
— |
|
— |
|
|
1,305 |
|
Net income (loss) |
26,115 |
|
43,657 |
|
69,772 |
|
(14,346 |
) |
7,164 |
(3,445 |
) |
5,204 |
|
(1,153 |
) |
|
63,196 |
|
Less: Net income attributable to noncontrolling interests |
(4,806 |
) |
(740 |
) |
(5,546 |
) |
— |
|
— |
— |
|
— |
|
— |
|
|
(5,546 |
) |
Net income (loss) attributable to |
21,309 |
|
42,917 |
|
64,226 |
|
(14,346 |
) |
7,164 |
(3,445 |
) |
5,204 |
|
(1,153 |
) |
|
57,650 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Earnings per share: |
|
|
|
|
|
|
|
|
|
|||||||||
Net income per share - basic |
|
|
|
|
|
|
|
|
$ |
0.61 |
|
|||||||
Net income per share - diluted |
|
|
|
|
|
|
|
|
$ |
0.61 |
|
|||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|||||||||
Basic |
|
|
|
|
|
|
|
|
|
94,878 |
|
|||||||
Diluted |
|
|
|
|
|
|
|
|
|
95,030 |
|
About
A global leader in fresh produce,
Webcast and Conference Call Information
An archived replay of the webcast will also be available shortly after the live event has concluded. The conference call can be accessed live by dialing +1 646 787 9445 or for international callers by dialing +44 203 936 2999. The access code is 710667.
A replay of the call will be available through
Forward-looking information
Certain statements made in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s beliefs, assumptions, and expectations of our future economic performance, considering the information currently available to management. These statements are not statements of historical fact. The words “believe,” “may,” “could,” “will,” “should,” “would,” “anticipate,” “estimate,” “expect,” “intend,” “objective,” “seek,” “strive,” “target” or similar words, or the negative of these words, identify forward-looking statements. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates, or expectations contemplated by us will be achieved. Such forward-looking statements are subject to various risks and uncertainties and assumptions relating to our operations, financial results, financial condition, business prospects, growth strategy and liquidity. Accordingly, there are, or will be, important factors that could cause our actual results to differ materially from those indicated in these statements. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, our actual results may vary materially from what we may have expressed or implied by these forward-looking statements. We caution that you should not place undue reliance on any of our forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made except as required by the federal securities laws.
1
2 This press release contains pro-forma financial information. The unaudited pro-forma consolidated financial statements for
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005650/en/
Investor Contact:
joregan@totalproduce.com
+353 1 887 2794
Media Contact:
philip.elwood@ogilvy.com
+1 202 423 7957
brian.bell@ogilvy.com
+353 87 2436 130
Source:
FAQ
What are Dole's Q1 2022 revenue and net income figures?
How did Dole's diluted EPS perform in Q1 2022?
What is Dole's outlook for 2022 revenue and adjusted EBITDA?